Statins in the prevention of cardiovascular events in patients with renal failure

Michele Buemi, Fulvio Floccari, Lorena Nostro, Susanna Campo, Chiara Caccamo, Alessio Sturiale, Carmela Aloisi, Maria Stella Giacobbe, Nicola Frisina

Research output: Contribution to journalArticlepeer-review


HMG-CoA reductase inhibitors (statins) are among the most widely used hypolypemizing drugs with a pleiotropic activity. Numerous clinical trials have demonstrated that statins can have a significant effect in the prevention of cardiovascular diseases in the general population. In patients with renal failure, this drug preserves the hypolypemizing efficacy found in the general population without increasing their unwanted side-effects. The re-analysis of data from epidemiological studies conducted on the general population has confirmed that statins provide cardiovascular protection also in subjects with renal failure. These data have been partly confirmed by the findings made by 4D (Die Deutsche Diabetes Dialyse Studie) and Alert studies, conducted on diabetic patients on dialysis and patients with renal transplants, respectively. The results of other studies, such as AURORA, SHARP, REnal and Vascular End stage Disease, and ESPLANADE, clearly indicate that statins prevent cardiovascular disease in patients with renal insufficiency, just as they do in the general population.

Original languageEnglish
Pages (from-to)7-13
Number of pages7
JournalCardiovascular and Hematological Disorders - Drug Targets
Issue number1
Publication statusPublished - Mar 2007


  • Cardiovascular disease (CVD)
  • Dialysis
  • HMG-coenzyme A reductase inhibitors
  • Nephropathic patients
  • Transplantation

ASJC Scopus subject areas

  • Molecular Medicine
  • Cardiology and Cardiovascular Medicine
  • Hematology
  • Pharmacology


Dive into the research topics of 'Statins in the prevention of cardiovascular events in patients with renal failure'. Together they form a unique fingerprint.

Cite this